TRAVERE THERAPEUTICS, INC.

TVTX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011
Operating Activities
Net Income $-59.7M $-47.9M $117.2M $-110.9M $-34.6M $-30.3M $-23.0K
Depreciation & Amortization $17.8M $16.1M $13.4M $5.4M $216.0K $124.9K
Depreciation $500.0K $100.0K $100.0K
Amortization $17.3M $16.0M $13.2M $5.3M $324.0K
Stock-Based Compensation $26.9M $29.1M $25.9M $15.9M $5.4M $22.4M
Net Cash from Operating Activities $7.4M $-3.4M $-1.4M $-45.9M $-17.6M $-2.7M $-689
Investing Activities
Capital Expenditures $887.0K $1.4M $22.0K $663.0K $117.0K $24.8K
Business Acquisitions $0 $615.0K $33.4M $29.2M $0
Net Cash from Investing Activities $45.6M $10.4M $-80.6M $-5.4M $-1.7M
Financing Activities
Dividends Paid
Stock Repurchases $0 $0 $2.3M $958.0K
Net Cash from Financing Activities $5.4M $-3.8M $101.6M $95.3M $29.0M $4.4M
Net Change in Cash $58.4M $3.2M $19.6M $12.2M $6.0M $1.3K
Free Cash Flow $6.5M $-4.9M $-1.4M $-46.5M $-17.7M $-2.8M
← Newer Page 2 of 2 Older →